Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.75 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.75 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.75 |
| ▸ | NT5E | P21589 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.64 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3955616 | 1.00 | ADORA3 (0.75) | ADORA3ADORA1ADORA2AADORA2BNT5E | |
| SCHEMBL30581189 | 0.92 | ADORA3 (0.80) | ADORA3ADORA1ADORA2AADORA2BNT5E | |
| SCHEMBL5396253 | 0.92 | ADORA3 (0.80) | ADORA3ADORA1ADORA2AADORA2BNT5E | |
| SCHEMBL7080746 | 0.92 | ADORA3 (0.80) | ADORA3ADORA1ADORA2AADORA2BNT5E | |
| SCHEMBL7080749 | 0.92 | ADORA3 (0.80) | ADORA3ADORA1ADORA2AADORA2BNT5E | |
| SCHEMBL4136507 | 0.92 | ADORA3 (0.80) | ADORA3ADORA1ADORA2AADORA2BNT5E | |
| SCHEMBL4806847 | 0.91 | PGK1 (0.71) | ADORA3ADORA1ADORA2AADORA2BTP53 | |
| SCHEMBL25361615 | 0.90 | ADORA3 (0.69) | ADORA3ADORA1ADORA2AADORA2BNT5E | |
| SCHEMBL26031390 | 0.90 | ADORA3 (0.69) | ADORA3ADORA1ADORA2AADORA2BNT5E | |
| SCHEMBL26031354 | 0.90 | ADORA3 (0.69) | ADORA3ADORA1ADORA2AADORA2BNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262176-B2 | Adenosine A3 receptor agonists | CV THERAPEUTICS, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| EP-1414837-B1 | ADENOSINE A3 RECEPTOR AGONISTS | CV THERAPEUTICS INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040116376-A1 | Adenosine A3 receptor agonists | CV THERAPEUTICS, INC. | 2004-06-17 | — | — | US | disclosed |
| EP-1414837-A1 | ADENOSINE A3 RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20030078232-A1 | Adenosine receptor A3 agonists | CV THERAPEUTICS, INC. | 2003-04-24 | — | — | US | disclosed |
| WO-2003014137-A1 | ADENOSINE A3 RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078232-A1 | Adenosine receptor A3 agonists | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885ADORA1 3/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.